Last updated: September 14, 2026
RHOPHYLAC is a plasma-derived human Rho(D) immune globulin marketed by CSL Behring. Its commercial position is supported by established obstetric use, a limited number of qualified suppliers, and manufacturing barriers associated with human plasma collection and fractionation. Its main constraints are mature-market demand, the absence of separately disclosed product revenue, competition from RhoGAM and other anti-D products, and limited scope for conventional patent exclusivity.
What is RHOPHYLAC and how is it used?
RHOPHYLAC contains human anti-D immunoglobulin, also called Rho(D) immune globulin or anti-D immune globulin. In the United States, the product is approved for:
- Prevention of Rh immunization in nonsensitized Rh-negative pregnant women.
- Prevention of Rh immunization after transfusion of Rh-positive blood or blood products.
- Treatment of immune thrombocytopenic purpura in Rh-positive, nonsplenectomized adults. [1]
The standard obstetric presentation is a 1,500 IU, or 300 microgram, dose. RHOPHYLAC can be administered intravenously or intramuscularly, which gives it an administration advantage in settings where rapid intravenous delivery is preferred. [1]
| Attribute |
RHOPHYLAC |
| Active ingredient |
Human Rho(D) immune globulin |
| Product type |
Plasma-derived biologic |
| U.S. sponsor |
CSL Behring AG |
| U.S. dosage form |
Injectable solution |
| Common dose |
1,500 IU, equivalent to 300 micrograms |
| Main markets |
Obstetrics, transfusion medicine, immune thrombocytopenia |
| Administration |
Intravenous or intramuscular |
| FDA pathway |
Biologics license application |
| Standalone revenue disclosure |
Not reported by CSL |
How large is the RHOPHYLAC market?
The relevant market is the anti-D immune globulin market rather than a conventional branded-drug category. Demand is determined by the number of Rh-negative pregnancies, use of prenatal and postpartum prophylaxis, transfusion events, and selected hematology applications.
The obstetric market is the core demand base. Anti-D prophylaxis is typically administered during pregnancy and after potentially sensitizing events, including delivery, miscarriage, abortion, trauma, invasive procedures, and transfusion. This creates recurring but episodic demand.
The market has four commercial characteristics:
- Demand is medically entrenched. Prevention of Rh sensitization remains a standard of care in many markets.
- Product supply depends on human plasma donors with sufficiently high anti-D antibody titers.
- Manufacturing is regulated and capital intensive.
- Unit demand is relatively predictable, but product sales can be affected by birth rates, practice guidelines, inventory cycles, and supply interruptions.
CSL Behring reports financial performance at broader business-segment levels and does not disclose RHOPHYLAC sales as a standalone line item. Public filings therefore do not support a product-specific revenue estimate or a verified year-by-year sales trajectory. CSL’s broader immunoglobulin business is exposed to plasma collection, fractionation capacity, reimbursement, and demand across multiple immunoglobulin products, making segment revenue an unsuitable proxy for RHOPHYLAC sales. [2]
What is the financial trajectory for RHOPHYLAC?
RHOPHYLAC appears to be a mature, cash-generative specialty biologic rather than a high-growth launch product. Its financial trajectory is likely shaped by market share, supply reliability, price realization, and manufacturing cost rather than rapid prescription expansion.
| Financial driver |
Directional effect on RHOPHYLAC |
| Stable obstetric prophylaxis |
Supports recurring demand |
| Declining or stagnant birth rates in developed markets |
Limits volume growth |
| Expanded use after sensitizing events |
Supports utilization per pregnancy |
| Plasma collection costs |
Pressures gross margin |
| Hospital and blood-bank contracting |
Pressures net price |
| Product shortages among competitors |
Can increase share and revenue |
| Generic substitution |
Limited near-term risk |
| Separate product reporting |
Prevents reliable revenue reconstruction |
The strongest positive financial factor is supply continuity. Hospitals and blood banks place a premium on products with validated manufacturing, established distribution, and dependable availability. A shortage affecting another anti-D product can shift purchases toward RHOPHYLAC.
The main structural risk is that obstetric use is linked to demographic volume. An aging population does not directly increase RHOPHYLAC demand. The product’s immune thrombocytopenia indication provides diversification, but that indication is narrower and competes with corticosteroids, thrombopoietin receptor agonists, intravenous immunoglobulin, and other hematology treatments.
What patents protect RHOPHYLAC?
RHOPHYLAC does not have the same patent profile as a chemically synthesized small-molecule drug. Its commercial protection is based primarily on biologic manufacturing expertise, plasma sourcing, process controls, regulatory approvals, and market access.
The FDA does not list biologic products in the Orange Book in the same manner as small-molecule drugs. RHOPHYLAC is licensed under a biologics license application and is therefore evaluated through the Purple Book and the abbreviated biosimilar framework under the Public Health Service Act. [3,4]
Publicly relevant protection categories include:
- Plasma donor qualification and collection systems.
- Anti-D antibody enrichment and fractionation.
- Viral inactivation and pathogen-reduction controls.
- Purification and formulation processes.
- Release testing and potency specifications.
- Manufacturing know-how and quality systems.
- Trademarks and regulatory approvals.
These protections can impose meaningful commercial barriers even when no blocking composition-of-matter patent remains active. They are harder for competitors to reproduce than a conventional tablet formulation, but they do not prevent an approved competitor from developing a separate manufacturing process.
When does RHOPHYLAC lose exclusivity?
RHOPHYLAC’s principal U.S. biologic exclusivity period has expired. The FDA’s initial U.S. approval is identified as 2001 in the prescribing information. Under the Biologics Price Competition and Innovation Act, an innovator biologic receives 12 years of reference-product exclusivity before a biosimilar may be approved, subject to the statutory framework. That period would have expired approximately in 2013. [1,4]
| Exclusivity issue |
RHOPHYLAC status |
| U.S. initial approval |
2001 |
| 12-year reference-product exclusivity |
Expired approximately 2013 |
| Small-molecule Hatch-Waxman exclusivity |
Not applicable |
| Orange Book patent listing |
Not the governing framework |
| Purple Book relevance |
Yes |
| Patent-based market protection |
Manufacturing and process dependent |
| Regulatory pathway for competitors |
Biosimilar or separate biologics pathway |
The expiry of reference-product exclusivity does not create automatic generic substitution. RHOPHYLAC is a biologic, and a competing anti-D product would need its own regulatory approval. Interchangeability also requires a specific FDA determination; it does not arise merely because the reference product’s exclusivity has ended.
Are there Paragraph IV challenges or biosimilar competitors?
Paragraph IV litigation is generally not the applicable framework for RHOPHYLAC. Paragraph IV certifications address patents listed in the Orange Book for small-molecule products. A competitor seeking approval of a comparable biologic would use the Public Health Service Act pathway and the statutory patent-exchange process associated with a biosimilar application. [3,4]
No FDA-approved biosimilar to RHOPHYLAC is identified in the publicly available FDA biosimilar framework cited here. The competitive risk therefore comes more immediately from other licensed Rho(D) immune globulin products than from a designated RHOPHYLAC biosimilar.
Potential competitors include:
- RhoGAM, associated with Kedrion Biopharma.
- MICRhoGAM, a lower-dose presentation used in selected obstetric settings.
- HyperRHO, marketed by Grifols.
- WinRho SDF, marketed by Sobi in selected markets.
- Regional plasma-derived anti-D products outside the United States.
These products are not automatically interchangeable with RHOPHYLAC. Differences may include indication scope, dose, route of administration, formulation, labeling, supply status, and contracting terms.
What formulation and manufacturing protections matter?
RHOPHYLAC is supplied as a ready-to-use injectable solution. The formulation itself is less likely to provide durable exclusivity than the integrated manufacturing system required to produce a safe and potent plasma-derived product.
The key barriers are:
Plasma supply
Anti-D immune globulin requires plasma from donors with appropriate antibody characteristics. The supply pool is limited, and collection volumes cannot be expanded as quickly as synthetic pharmaceutical production.
Fractionation and purification
Manufacturers must achieve consistent antibody potency while removing unwanted plasma proteins and controlling aggregation, contaminants, and viral risk.
Viral safety
Validated viral inactivation and removal steps are essential. Any process change may require comparability work, regulatory review, and additional validation.
Potency and lot consistency
Dose reliability is commercially important because underdosing may fail to prevent Rh sensitization while excessive dosing increases cost and exposure.
Regulatory manufacturing history
Hospitals and blood banks favor products with a long record of approved production and stable quality performance. This creates switching friction even after formal exclusivity ends.
What is the Orange Book and FDA status of RHOPHYLAC?
RHOPHYLAC is not primarily an Orange Book product. Its regulatory status is governed by its biologics license and the FDA’s biologic-product databases. The product’s FDA labeling identifies CSL Behring AG as the license holder and includes the obstetric, transfusion, and immune thrombocytopenia indications. [1]
The practical consequences are:
- No conventional Orange Book patent-linkage strategy.
- No standard abbreviated new drug application substitution pathway.
- No automatic pharmacy substitution based on generic equivalence.
- Competitors must establish safety, purity, and potency through a biologics pathway.
- Interchangeability requires a separate FDA designation.
What patent litigation affects RHOPHYLAC?
No major RHOPHYLAC-specific U.S. patent litigation is identified in the cited regulatory and corporate sources. The absence of Orange Book listing reduces the likelihood of a conventional Hatch-Waxman litigation cycle.
Future disputes would more likely involve:
- Biosimilar patent-exchange litigation.
- Process patents covering plasma fractionation or purification.
- Trade-secret allegations involving manufacturing know-how.
- Trademark or product-labeling disputes.
- Contracting and supply disagreements.
Process litigation could delay a competitor without creating a permanent product monopoly. Plasma-derived biologics are difficult to replicate commercially, but the relevant protection is often distributed across regulatory controls, proprietary know-how, supplier relationships, and production capacity.
Which companies are challenging RHOPHYLAC commercially?
The principal commercial challengers are other anti-D immune globulin suppliers rather than generic manufacturers.
| Competitor |
Competitive relevance |
| RhoGAM/MICRhoGAM |
Established obstetric competitor |
| HyperRHO |
Plasma-derived anti-D alternative |
| WinRho SDF |
Alternative with obstetric and hematology relevance in selected markets |
| Regional anti-D products |
Can influence non-U.S. pricing and supply |
| Future biosimilar developers |
Longer-term regulatory risk |
The most credible near-term threat is share erosion through hospital tenders, distributor contracts, and supply-based switching. A biosimilar could create stronger price pressure, but product-specific development requirements and limited market size reduce the economic appeal compared with larger immunoglobulin categories.
How does RHOPHYLAC compare with competing anti-D products?
RHOPHYLAC’s strongest differentiator is its intravenous and intramuscular administration flexibility. Its broad U.S. labeling also supports use across obstetric, transfusion, and immune thrombocytopenia settings. RhoGAM has strong brand recognition in obstetrics, while WinRho has a distinct position in immune thrombocytopenia in markets where it is approved.
| Factor |
RHOPHYLAC |
RhoGAM |
WinRho SDF |
| Product class |
Human anti-D immunoglobulin |
Human anti-D immunoglobulin |
Human anti-D immunoglobulin |
| Obstetric use |
Yes |
Yes |
Yes, where labeled |
| ITP use |
Yes |
Generally not the principal commercial position |
Yes, where labeled |
| IV administration |
Yes |
Product and indication dependent |
Yes |
| Core advantage |
Broad labeling and route flexibility |
Brand familiarity and obstetric presence |
Hematology positioning |
| Main risk |
Mature demand and contracting |
Competition and supply |
Safety, indication, and market-specific limits |
What generic launch risks exist for RHOPHYLAC?
A conventional generic launch is unlikely because RHOPHYLAC is a biologic. The more relevant scenarios are:
- A competing licensed anti-D product wins hospital contracts.
- A biosimilar or follow-on biologic receives FDA approval.
- A plasma supplier expands capacity and enables lower-cost competition.
- A competitor obtains an interchangeability designation.
- A shortage causes forced substitution and changes purchasing behavior.
The highest-probability scenario is gradual share competition among existing anti-D products. The highest-impact scenario is an interchangeable follow-on product, which could materially increase payer and hospital leverage. The timing of that scenario remains uncertain because no approved RHOPHYLAC biosimilar is identified in the cited FDA materials.
What is the geographic coverage of RHOPHYLAC?
RHOPHYLAC has international commercial exposure, but approval, labeling, reimbursement, and competitive intensity vary by country. The United States is a key market because of its large healthcare system and established anti-D prophylaxis use. European markets are also relevant, although national procurement and reimbursement systems can place greater pressure on price.
Geographic performance depends on:
- National Rh prophylaxis guidelines.
- Birth rates and maternal-care volumes.
- Hospital tender structures.
- Local plasma-product regulation.
- Availability of competing anti-D products.
- Import and supply-chain requirements.
What licensing deals involve RHOPHYLAC?
No major RHOPHYLAC-specific licensing transaction is identified in the cited CSL corporate reporting. CSL markets RHOPHYLAC within its broader plasma-derived and immunoglobulin portfolio. The absence of a disclosed product-level licensing deal limits transaction-based valuation analysis.
Potential strategic value lies in distribution rights, regional supply agreements, and manufacturing access rather than in a conventional patent license.
Key Takeaways
- RHOPHYLAC is a mature plasma-derived anti-D biologic marketed by CSL Behring.
- Its principal demand base is Rh prophylaxis in pregnancy, with additional use in transfusion medicine and immune thrombocytopenia.
- Standalone product revenue is not disclosed, so a verified product-level financial trajectory cannot be calculated from CSL filings.
- U.S. biologic reference-product exclusivity expired approximately in 2013 based on the 2001 initial approval.
- Paragraph IV litigation and Orange Book patent linkage are not the primary competitive framework.
- Manufacturing, plasma supply, quality systems, and regulatory history provide the main barriers to entry.
- Existing anti-D products are the principal commercial competitors.
- No FDA-approved RHOPHYLAC biosimilar is identified in the cited sources.
- The most probable commercial risk is gradual hospital-contract share erosion, not a conventional generic launch.
FAQs About RHOPHYLAC Market and Patent Risk
Is RHOPHYLAC a biosimilar?
No. RHOPHYLAC is an original licensed plasma-derived biologic. A future comparable product would need to obtain separate FDA approval under a biologics pathway.
Can pharmacies automatically substitute a competing anti-D product for RHOPHYLAC?
Automatic substitution depends on the product’s regulatory status and any FDA interchangeability designation. Approval as a biologic competitor alone does not establish automatic substitution.
Does RHOPHYLAC have an Orange Book patent expiration date?
No conventional Orange Book expiration date governs RHOPHYLAC because it is regulated as a biologic rather than as a small-molecule drug listed through the Hatch-Waxman framework.
What is the biggest supply risk for RHOPHYLAC?
The main supply risk is constrained access to suitable anti-D plasma donors, followed by fractionation capacity, manufacturing disruptions, and regulatory controls affecting lot release.
Is RHOPHYLAC revenue reported separately by CSL Behring?
No. CSL reports broader business and product-group financial results rather than a separately audited RHOPHYLAC revenue line.
References
-
U.S. Food and Drug Administration. (2024). Rhophylac prescribing information. CSL Behring AG.
-
CSL Limited. (2024). Annual report 2024. CSL Limited.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/
-
Public Health Service Act, 42 U.S.C. § 262. (2024). Biological product licenses and abbreviated approval pathways.
